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OBJECTIVES: Asthma is a chronic inflammatory lung disease characterized by bronchial hyperresponsiveness and
airflow obstruction. Genetic and oxidative stress factors, in addition to pulmonary and systemic inflammatory
processes, play a pivotal role in the pathogenesis of asthma. The products of the multidrug resistance-1 gene protect
lung tissue from oxidative stress. Here, we aimed to evaluate the association between the multidrug resistance-1
gene C4T polymorphism and asthma with regard to oxidative stress-related parameters of asthmatic patients.
METHODS: Forty-five patients with asthma and 27 healthy age-matched controls were included in this study.
Blood samples were collected in tubes with ethylenediaminetetraacetic acid. DNAwas extracted from the blood
samples. The multidrug resistance-1 gene polymorphism was detected by polymerase chain reaction and a
subsequent enzyme digestion technique. The serum levels of total oxidant status and total antioxidant status
were determined by the colorimetric measurement method.
RESULTS: The heterozygous polymorphic genotype was the most frequent in both groups. A significant difference in
the multidrug resistance-1 genotype frequencies between groups indicated an association of asthma with the TT
genotype. A significant difference between groups was found for wild type homozygous participants and carriers of
polymorphic allele participants. The frequency of the T allele was significantly higher in asthmatic patients. The
increase in the oxidative stress index parameter was significant in the asthma group compared with the control group.
CONCLUSIONS: The multidrug resistance-1 gene C/T polymorphism may be an underlying genetic risk factor for
the development of asthma via oxidant-antioxidant imbalance, leading to increased oxidative stress.
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’ INTRODUCTION
Multidrug resistance (MDR) genes constitute a class of genes
that play a critical role in multiple drug resistance in eukaryotic
cells (1). The MDR-1 gene is located on chromosome 7q21 and
plays a role in cellular regeneration (2,3). It has been reported
that products of the MDR-1 gene, such as multidrug resistance-
associated protein-1 (MRP1), P-glycoprotein (P-gp), and lung
resistance-related protein (LRP), act as anti-oxidants and protect
lung tissue against oxidative stress (4).
Asthma is a chronic inflammatory lung disease character-
ized by smooth muscle contraction, variable airflow obstruc-
tion, mucus hypersecretion and bronchial hyperreactivity
associated with airway remodeling (5,6). Oxidative stress is
one of the clearly identified pathophysiological mechanisms
of this disease (5). Oxidant-antioxidant imbalances lead to
pathophysiological effects associated with asthma, such as
vascular permeability, mucus hypersecretion, smooth muscle
contraction, and epithelial shedding. It has been previously
shown that oxidant-antioxidant imbalance is associated with
asthma (7), and it is also known that asthma has a strong
genetic component (8).
No studies have previously investigated the relationship
between MDR-1 gene polymorphisms and asthma. We
aimed to investigate the association between the MDR-1
gene C4T polymorphism and asthma with regard to
clinical parameters and oxidative stress indices in asthmatic
patients.DOI: 10.6061/clinics/2015(10)02
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’ MATERIALS AND METHODS
Participants
Forty-five patients with asthma, who presented to
Dumlupınar University Medical Faculty, Department of
Chest Diseases, Kütahya (a city located in the Aegean part
of Turkey) and Yedikule Chest Diseases and Thoracic
Surgery Training and Research Hospital, Department of
Chest Diseases, I˙stanbul (a city located in the Marmara-
northern-west region of Turkey), and 27 healthy age-
matched control participants were included in this study.
The asthma diagnosis was established on the basis of the
criteria proposed by the Global Initiative for Asthma (GINA)
guidelines. All participants were ethnically Caucasian.
Individuals who had comorbidities were excluded from the
study. All procedures were explained to the subjects, and
written informed consent was obtained from all participants.
The study protocol conformed to the ethical guidelines of the
Declaration of Helsinki and was approved by the Clinical
Research Ethics Committee of Abant I˙zzet Baysal University.
Both groups were evaluated by several clinical parameters,
as follows: age; gender; body mass index (BMI; kg/m2);
asthma control test (ACT) score; pulse; oxygen (O2)
saturation; systolic and diastolic blood pressure; forced vital
capacity (FVC; ml, %); forced expiratory volume in 1 second
(FEV1; ml, %); FEV1/FVC; forced expiratory flow at
25-75% of the FVC (FEF25-75; %); and peak expiratory flow
(PEF; ml, %). All individuals were assessed by the criteria
according to the asthma control test to calculate the ACT
score. For this purpose, the patients were asked the following
questions: in the past 4 weeks 1) How often did your asthma
limit you at work, school or at home?; 2) How often have you
had shortness of breath?; 3) How often did your asthma
symptoms (wheezing, coughing, shortness of breath, chest
tightness or pain) wake you up at night or earlier than usual
in the morning?; 4) How often have you used your rescue
inhaler or nebulizer medication?; and 5) How would you
rate your asthma control during the past 4 weeks? The
patients scored each question from 1 to 5. The ACT scores
were grouped as well controlled (score of 25), partly
controlled (scores 20-24) and uncontrolled (score p19) (9).
Total Antioxidant Status-Total Oxidant Status
Analysis and OSI Calculation
Blood samples were collected in tubes without ethylenedia-
minetetraacetic acid (EDTA). After centrifugation, serum from
each individual was stored at -80 ˚C until ELISA analysis.
Serum levels of the total oxidant status (TOS)- total antioxidant
status (TAS) were determined by the colorimetric measure-
ment method (Ral Assay Diagnostics). The oxidative stress
index (OSI) was calculated according to the following formula
(10): OSI (arbitrary unit)=TOS (mmol H2O2 Equiv./L) /TAS
(mmol. Trolox Equiv./L).
Genotyping
Deoxyribonucleic acid isolation. Blood samples from 72
participants (45 asthma, 27 control) were collected in tubes with
EDTA. DNA was isolated from peripheral blood leukocytes
using a standard phenol/chloroform extraction method.
Polymerase chain reaction. Polymerase chain reaction
(PCR) was used to detect the C3435T single nucleotide
polymorphism (SNP). A PCR assay using the forward primer
MDR1F 5’-TGC TGG TCC TGA AGT TGA TCT GTG A AC-
3’ and the reverse primer MDR1R 5’-ACA T TA GGC AGT
GAC TCG ATG A AG GCA-3’ was performed with 10
buffer, 1.5 mM MgCl2, 0.2 mM of each dNTP and 1 U Taq
DNA polymerase (11). PCR amplification consisted of an
initial denaturation for 2 min at 94 ˚C followed by 35 cycles of
denaturation at 94 ˚C for 30 s, annealing at 60 ˚C for 30 s, and
extension at 72 ˚C for 30 s. Terminal elongation was
performed at 72 ˚C for 4 min. The digestion of a 248-bp
PCR product with the restriction enzyme MboI for 2 h at
37 ˚C followed this step. The digested products were
separated on a 3% agarose gel with ethidium bromide.
Subsequently, the restriction fragments were identified using
the UVI Gel Documentation system. The fragments obtained
were 238 bp for the T/T genotype, 172 bp and 60 bp for the
C/C genotype, and 238 bp, 172 bp and 60 bp for the C/T
genotype (12).
Statistical analysis. Statistical analyses were performed
using the SPSS (Statistical Package for Social Sciences,
Chicago, IL, USA) 16.0 package program. Clinical and TAS-
TOS-OSI parameters are presented as the mean±standard
error of the mean (SEM). The significance of the observed
genotype frequencies was evaluated according to the Hardy-
Weinberg rule by comparison of the expected genotype
frequencies. Hardy-Weinberg equilibrium was evaluated by
the chi-square test. Chi-square analysis was used to test the
association between asthma and the C3435T polymorphism of
the MDR1 gene. A Mann-Whitney U test was used to
compare the means of TAS, TOS and OSI parameters between
groups. ANOVA was used to determine differences in the
TAS, TOS and OSI parameters between genotypes in both
groups. The odds ratio for the Tallele between the groups was
calculated by the chi-square test. All p values o0.05 were
considered significant.
’ RESULTS
No significant difference was observed for the clinical
parameters between the groups (Table 1). In the asthma and
control groups, the most frequent genotype was the hetero-
zygous CT (n=27 and n=14, respectively). In both the asthma
and control groups, homozygous wild type and homozygous
polymorphic genotypes were less frequent. The most remark-
able difference between the groups in terms of genotype
frequency was that TTwas observed in 9 patients in the asthma
group and 1 in the control group. The distribution of the
frequencies of the genotype for the MDR-1 gene C/T
polymorphism in the asthma and control groups was
compatible with the Hardy-Weinberg equilibrium (p40.05;
Table 3). The frequencies of MDR-1 genotypes in asthmatic
patients and in control subjects are shown in Table 2. The
distribution of MDR-1 genotypes were found to be 20.0% (9) for
CC, 60.0% (27) for CT, and 20.0% (9) for TT in the asthma group
and 44.4% (12) for CC, 51.9% (14) for CT, and 3.7% (1) for TT in
the control group. The difference of the MDR-1 genotype
frequencies between groups indicates an association of asthma
with the TT genotype (X2=6,881; df=2; p=0,032; Table 3).
When the genotype frequency of homozygous poly-
morphic participants and wild type participants in the
asthma group were compared with controls, there was no
significance, although the level of significance was very close
to the alpha level (X2=3.747; df=1; p=0.053). An association
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between groups was found when a similar comparison was
made between wild type homozygous participants and
polymorphic allele participants (odds ratio for TT=3.19;
95% CI=0.11-0.902; p=0.027; Table 3).
The allele frequencies for the MDR-1 gene in asthmatic
patients and control subjects are shown in Table 2. The
distribution for the MDR-1 gene C alleles was 50.0% (45) in
the asthma group and 70.37% (38) in the control group. The
distribution for the T alleles was 50.0% (45) in the asthma
group and 29.63% (16) in the control group. There was a
significant difference between the groups regarding allele
frequency (X2=5.736; df=1; p=0.017; Table 3). The frequency
of the T allele was significantly higher in asthma patients
than in the control group (odds ratio for TT=3.2; 95%
CI=1.1-9.2; p=0.027).
Serum levels of TAS and TOS
The serum levels of TAS in the asthma and control groups
were as follows: 2.40±0.1 mmol. Trolox Equiv/L, 2.38±0.17
mmol. Trolox Equiv/L. No significant difference was found
between the groups in terms of TAS (p=0.793; Figure 1).
The serum levels of TOS in the asthma and control groups
were as follows: 51.44±4.38 mmol H2O2 Trolox Equiv./L,
24.76±2.63 mmol H2O2 Trolox Equiv./L. The increase in the
serum level of TOS in the asthma group was significant
compared with the control group (p=0.000; Figure 2).
The OSI parameters in the asthma and control groups were
as follows: 24.26±2.58 TOS/TAS, 11.12±1.39 TOS. The
increase in the OSI parameter was significant in the asthma
group compared with the control group (p=0.000; Figure 3).
In both the asthma patients and the control groups, no
significant difference was observed among the three geno-
types in terms of TAS, TOS and OSI (p40.05).
’ DISCUSSION
Asthma is a heterogeneous disorder, and a combination of
environmental and genetic factors play a role in the
pathogenesis of this disease (5,13). Although chronic
inflammation and oxidative stress are the key mechanisms
in the development of asthma, it is now known that the vast
majority of asthma cases are caused by interactions between
genetic and environmental risk factors (14-17). Furthermore,
recent studies have revealed that multiple gene loci are
involved in the etiology of asthma, and SNPs may be
associated with the development of asthma (5,18).
To date, over 50 SNPs have been reported for the MDR-1
gene, and the C3435T SNP located in exon 26 of the MDR-1
gene has been shown to be associated with P-gp levels (1,19).
P-gp, one of the products of the MDR-1 gene, is a
transmembrane protein that acts as an ATP-driven efflux
pump (1,2,20). This pump prevents the intracellular accumula-
tion of toxic substances, drugs and metabolites by effluxing
them from intracellular to extracellular areas (21,22). Therefore,
P-gp has a protective role against oxidative stress by playing a
role in combating the toxic effects of endogenous or exogenous
irritant substances and in the removal of oxidative stress
metabolites (23,24). It has been reported that the 3435C4T
polymorphism of the MDR-1 gene results in a decreased
expression of P-gp in T/T homozygote individuals compared
Table 2 - Hardy-Weinberg equilibrium of the MDR gene C/T polymorphism.
Asthma Control
Allele Expected Observed Expected Observed
Common homozygotes CC 11.25 9 13.37 12
Heterozygotes CT 22.5 27 41.7 14
Rare homozygotes TT 11.25 9 2.37 1
p=0.1797 p=0.2059
Table 1 - Comparisons of characteristics among the genotypes in asthmatic patients.
MDR C3435T polymorphism
CC CT TT
Age, years 39.44 ± 16.85 41.92 ± 14.18 42.44 ± 14.1
Female 19 32 9
Male 2 9 1
BMI (kg/m2) 29.59 ± 5.27 27.99 ± 5.91 14.44 ± 6.67
ACT (points) 15.44 ± 14.14 16.33 ± 4.53 15.78 ± 5.23
Pulse 85.12 ± 8.06 87.54 ± 12.8 87.00 ± 2.58
Saturation (%) 97.75 ± 1.03 97.31 ± 1.78 96.80 ± 1.79
SBP (mm Hg) 116.67 ± 14.14 116.67 ± 14.41 121.40 ± 14.47
DBP (mm Hg) 77.44 ± 10.19 76.89 ± 12.66 74.60 ± 8.35
FVC (%) 72.17 ± 18.70 84.25 ± 16.70 81.78 ± 13.36
FEV1 (%) 71.16 ± 22.28 79.98 ± 18.94 78.39 ± 16.20
FEV1/FVC (mL/mL) 82.90 ± 15.63 77.63 ± 12.42 79.85 ± 10.46
FEF 25-75 (%) 59.71 ± 37.23 60.30 ± 27.56 40.06 ± 29.31
PEF (%) 68.93 ± 29.51 64.54 ± 18.74 66.1 ± 27.33
TAS mmol. Trolox Equiv./L 2.43 ± 1.05 2.1 ± 1.02 3.09 ± 1.14
TOS mmol. Trolox Equiv./L 42.9 ± 20.64 51.2 ± 28.7 60.6 ± 32.6
OSI TOS mmol/l / TAC mmol of Trolox X 100 2018 ± 1412 2756 ± 1920 1988 ± 866
ACT: Asthma control test, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, FVC: Forced vital capacity, FEV1: Forced expiratory volume in one
second, FEF25-75: Forced expiratory flow at 25-75% of the FVC, PEF: Peak expiratory flow, TAS: Total antioxidant status, TOS: Total antioxidant status,
OSI: Oxidative stress index.
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with C/C homozygotes. Furthermore, a decreased expression
of intestinal P-gp in T/T homozygote subjects was shown in a
study by Hoffmeyer et al. (25). In another study by Dogan
et al. (1), it was shown that both MDR-1 mutant homozygous
(TT) and heterozygous (CT) polymorphisms were significantly
more frequent in patients with chronic obstructive pulmonary
disease (COPD). In a recent study, Toru et al. (26) reported an
increase in the frequency of the TT genotype of the MDR-1
gene in COPD patients and suggested that the MDR-1 gene
C/T polymorphism may play a role in COPD development.
Today, it is well known that both COPD and asthma are
characterized by chronic inflammation and remodeling of the
airways (27,28). Moreover, a common pathogenetic basis for
asthma and COPD is well defined based on overlapping
clinical characteristics and the association of genes common for
both of these diseases (29). In our study, an increased
frequency of the TT genotype was observed in patients with
asthma. We suggest that this increase may result in an
increased exposure to oxidative stress and may be an
underlying risk factor for asthma development. In addition,
our study describes for the first time the frequency of the
MDR-1 gene C4T polymorphism in asthma. It would be
useful to show tissue P-gp expression in the study participants
using PCR, in-situ hybridization, dot blot or immunohisto-
chemical methods, but this step could not be performed
because of technical issues; this is a limitation of our study.
Organisms are protected against oxidative stress via
enzymatic and non-enzymatic antioxidative mechanisms,
and normally, there is a balance between the rates of free
radical formation and their removal by antioxidant enzymes
and molecules (30,31). Therefore, the oxidative status of
biological samples is accepted as an indicator of oxidative
stress. In this regard, the measurement of TOS, TAS and OSI
are the most common procedures that are reported to
evaluate oxidative stress (30,32). In our study, we showed
that the TT genotype of the MDR-1 gene with the C3435T
polymorphism is associated with asthma. Additionally, we
found that the blood levels of TOS and OSI were significantly
higher in this genotype, which led to higher oxidative stress
in asthmatic patients than in the control group. Therefore, the
TT genotype may have an effect on the phenotype of the
MDR-1 protein and may lead to increased oxidative stress.
We can conclude that at least a proportion of this increase in
oxidative stress in asthma patients may arise from the
functional C3435T polymorphism of the MDR1 gene.
Finally, we can conclude that an increased T allele
frequency in the MDR-1 gene may result in an increased
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Figure 1 - Serum levels of TAS in the control and asthma groups.
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Figure 2 - Serum levels of TOS in the control and asthma groups.
***, The significance between the control and asthma group,
po0.005 (Mann Whitney U test).
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Figure 3 - The oxidative stress index (OSI) of the L, I/R, O3+L and
O3+I/R groups. ***, The significance between the control and
asthma group, po0.005 (Mann Whitney U test).
Table 3 - Genotype and allele frequencies of theMDR C/T
polymorphism.
Asthma Control
n % n %
Genotype Frequency
MDR C/T polymorphism
CC 9 20.0 12 44.4
CT 27 60.0 14 51.9
TT 9 20.0 1 3.7
Total 45 100 27 100
X2=6.881; df=2; p=0.032
CC and CT 36 80.0 26 96.3
TT 9 20.0 1 3.7
Total 45 100 27 100
X2=3.747; df=1; p=0.053
CC 9 20.0 12 44.4
CT and TT 36 80.0 15 55.6
Total 45 100 27 100
X2=4.881; df=1; p=0.027
Allele Frequency
MDR C allele 45 50.0 38 70.37
MDR T allele 45 50.0 16 29.63
X2=5.736; df=1; p=0.017
MDR, Multidrug resistance; df, degrees of freedom
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exposure to oxidative stress in asthmatic patients. Thus, the
MDR-1 gene C/T polymorphism may play a role in the
development of asthma as a result of oxidant-antioxidant
imbalance in favor of increased oxidative stress. However,
further studies are needed to support our results and clarify
the role of the MDR-1 gene polymorphism in asthma.
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